Per Bo Pedersen Fischer
Chief Executive Officer at Helion Biotech ApS
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jens Christian Jensenius | M | 82 |
Helion Biotech ApS
 Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark.
Azanta Danmark A/S
 Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | 16 years |
| Steffen Thiel | M | 63 |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark.
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | 16 years |
| Emmanuelle Coutanceau | M | 44 |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Ingelise Saunders | F | 75 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Stephen Davies | M | 74 |
University of Oxford
| 28 years |
| Sten Verland | M | 67 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Michael Darsley | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Carsten Schou | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Jeppe Vesti Christensen | M | - |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | 16 years |
| Mona Annelie Sylvén-Troedsson | F | 75 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Bent Østergaard | M | 79 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Kabeer Aziz | M | 34 |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | - |
| Gunnar Lindahl | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 14 years |
| Patrik Sobocki | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 2 years |
| Christopher Gagliardi | M | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Evans | M | - |
University of Oxford
| 9 years |
| Nigel L. Clarke | M | - |
University of Oxford
| 4 years |
| Kathryn Farrar | F | 47 |
University of Oxford
| 5 years |
| Taksz Ildiko | M | 55 |
University of Oxford
| 5 years |
| Mark Carney | M | 59 |
University of Oxford
| 3 years |
| Martin N. Bonde | M | 61 |
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | - |
| R. Alan B. Ezekowitz | M | 70 |
Azanta Danmark A/S
Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | - |
| Philip Shapiro | M | 49 |
University of Oxford
| 3 years |
| Truman Packard | M | - |
University of Oxford
| 7 years |
| William Ashby | M | - |
University of Oxford
| 4 years |
| Rupert Charles de Borchgrave d'Altena | M | - |
University of Oxford
| 7 years |
| Byron Auguste | M | 56 |
University of Oxford
| 4 years |
| Antony J. Fairbanks | M | - |
University of Oxford
| 3 years |
| Doron Junger | M | - |
University of Oxford
| 6 years |
| Argyris Stasinakis | M | - |
University of Oxford
| 8 years |
| Soo Chuen Tan | M | - |
University of Oxford
| 3 years |
| Girindre Beeharry | M | - |
University of Oxford
| 2 years |
| Faisel Ahmed Gergab | M | - |
University of Oxford
| 4 years |
| Jim Maun | M | - |
University of Oxford
| 3 years |
| Mark Jennings | M | 63 |
University of Oxford
| 3 years |
| Siddhartha Sandilya | M | - |
University of Oxford
| 3 years |
| Houman Ashrafian | M | 49 |
University of Oxford
| 4 years |
| Paul Woodman | M | - |
University of Oxford
| 4 years |
| Yau Hool | M | - |
University of Oxford
| 4 years |
| Simon William Moore | M | 46 |
University of Oxford
| 10 years |
| Benjamin R. Little | M | - |
University of Oxford
| 1 years |
| Rajesh Swaminathan | M | - |
University of Oxford
| 2 years |
| Turi Munthe | M | 48 |
University of Oxford
| 4 years |
| Julian Graeme Ross | M | 59 |
University of Oxford
| 4 years |
| Bruce Niven | M | - |
University of Oxford
| 4 years |
| Seb D'Avanzo | M | - |
University of Oxford
| 4 years |
| Zain Azmir Zain Azahari | M | - |
University of Oxford
| 3 years |
| Nailesh Rambhai | M | - |
University of Oxford
| 3 years |
| Raj Dutta | M | - |
University of Oxford
| 3 years |
| Alex Murray | M | - |
University of Oxford
| 4 years |
| Michael Drexler | M | - |
University of Oxford
| 4 years |
| Martin Bavinton | M | - |
University of Oxford
| 4 years |
| Michal Myck | M | - |
University of Oxford
| 4 years |
| Atiff Gilli | M | 49 |
University of Oxford
| 2 years |
| Lucia Gunn | F | - |
University of Oxford
| 3 years |
| Robin Bell Jones | M | - |
University of Oxford
| 5 years |
| Frank Lampen | M | - |
University of Oxford
| 3 years |
| Gavin Screaton | M | - |
University of Oxford
| 3 years |
| Ben Kilmartin | M | - |
University of Oxford
| 4 years |
| Ian Alistair Jensen-Humphreys | M | - |
University of Oxford
| 4 years |
| Will Pearson | M | - |
University of Oxford
| 4 years |
| Jamie Metzl | M | - |
University of Oxford
| 4 years |
| Richard Sanders | M | 48 |
University of Oxford
| 3 years |
| Julian Mitchell | M | - |
University of Oxford
| 3 years |
| Thomas Casdagli | M | 47 |
University of Oxford
| 4 years |
| Eduardo Bruno Martins | M | 61 |
University of Oxford
| 3 years |
| James Mitchell | M | 51 |
University of Oxford
| 4 years |
| Azeem Azhar | M | - |
University of Oxford
| 4 years |
| Ole Bitsch-Jensen | M | - |
Helion Biotech ApS
Helion Biotech ApS Pharmaceuticals: MajorHealth Technology Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark. | 2 years |
| Alan Jonathan Dodsworth | M | - |
University of Oxford
| 4 years |
| Pedro Dornelles Arnt | M | 50 |
University of Oxford
| 2 years |
| Ahmad Atwan | M | - |
University of Oxford
| 2 years |
| Maxim Shashenkov | M | - |
University of Oxford
| 4 years |
| John Lachlan Gray MacDougall | M | - |
University of Oxford
| 4 years |
| David Kneale | M | - |
University of Oxford
| 4 years |
| Jun Li | M | 63 |
University of Oxford
| 3 years |
| Sarah Friar | F | 51 |
University of Oxford
| 4 years |
| Andrew Sillitoe | M | 50 |
University of Oxford
| 1 years |
| Tycho Peterson | M | 51 |
University of Oxford
| 2 years |
| Colin Jamie Brammer | M | - |
University of Oxford
| 3 years |
| Jeffrey Moore | M | - |
University of Oxford
| 4 years |
| Patrick Keefe | M | - |
University of Oxford
| 2 years |
| Chor Shan Lai | F | 51 |
University of Oxford
| 3 years |
| Ian Gardiner | M | - |
University of Oxford
| 4 years |
| Deepak Ramachandran | M | - |
University of Oxford
| 4 years |
| Thomas Wei | M | 48 |
University of Oxford
| 2 years |
| Mark Brooker | M | 52 |
University of Oxford
| 4 years |
| Scott Weiner | M | - |
University of Oxford
| 6 years |
| Natalia Gurushina | M | - |
University of Oxford
| 5 years |
| Carlos Elizondo Mayer-Serra | M | 62 |
University of Oxford
| 3 years |
| Robert Swerling | M | - |
University of Oxford
| 3 years |
| Carolyn Anne Prowse | F | 52 |
University of Oxford
| 4 years |
| Vishal Agarwal | M | 49 |
University of Oxford
| 1 years |
| Archil Kontselidze | M | - |
University of Oxford
| 2 years |
| Paolo Andrea Mutti | M | 59 |
University of Oxford
| 3 years |
| Timothy Ashlin | M | 47 |
University of Oxford
| 3 years |
| Rebecca Gibson | F | - |
University of Oxford
| 3 years |
| Jonathan Montagu | M | - |
University of Oxford
| 5 years |
| Clare Hawkins | F | - |
University of Oxford
| 4 years |
| Georgina Wells | F | - |
University of Oxford
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 83 | 83.00% |
| Denmark | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Per Bo Pedersen Fischer
- Personal Network
